News

Novavax will update its protein-based COVID-19 vaccine, but maintains the current vaccine is effective against current and future variants.

The agency would like to begin using individual risk-based questions to reduce the risk of transfusion-transmitted HIV.

The federal agency does not want clinicians utilizing this neutralizing antibody as newer, circulating COVID-19 strains and efficacy against them is limited.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted to move toward a unified strain composition for COVID-19 primary and booster vaccines.

In the CDC’s latest Morbidity and Mortality Weekly Report, investigators reported the Moderna and Pfizer-BioNTech updated vaccines helped prevent acute infection from the latest Omicron mutations.

The Pfizer-BioNTech COVID-19 vaccine was associated with rare instances of myo/pericarditis and acute kidney injury, according to a nationwide study in New Zealand that confirmed the safety profile of the vaccine.

Investigators identify a mechanism that’s vital to the progression of alcohol-related hepatitis, paving the way for new treatments.

Sky-high costs with little wiggle room to negotiate mean fidaxomicin remains underprescribed for recurrent C diff, despite favorable outcomes.

If approved on its March PDUFA date, rezafungin could be the first new Candida treatment option in over a decade.

The new guidance looks at preexposure and postexposure prophylaxis as well as treatment for COVID-19.

A recreation of a failed staph vaccine trial unveiled that previous exposure to S aureus made the vaccine candidate ineffective.

A new study demonstrated continuous neutralization after 3 doses.

“Vaccination coverage among pregnant women remains a priority,” the study authors noted.

Rapidly distributing vaccines to at least 1/3 of at-risk populations, in addition to increasing tasting and contact tracing, may adequately stop the spread of mpox.

In this week’s meeting, FDA is expected to ask their advisory committee to consider changes to simplify the vaccination schedule and look at delivering it annually, much like an influenza vaccine.

What factors contribute to post-COVID-19 conditions (“long COVID”)? Can vaccination before or after a COVID-19 infection decrease the risk of long COVID?

An analysis of the actions taken to combat antimicrobial resistance in 114 countries finds national action plans easier to develop than to implement.

A Chinese epidemiologist made this claim this weekend as the country gathers for its Lunar New Year celebrations.

Reported reasons adults had not received a bivalent COVID-19 booster dose differed across age groups.

Click on the slideshow images to read the full stories featured in this weekly infectious disease recap.

A mathematical modeling study for HPTN 083 demonstrated both forms of PrEP vs not taking anything remained efficacious in preventing infection.

Although vaccine rates overall remain high, a new report shows a reduction 2 years in a row, leaving thousands of children not vaccinated against vaccine-preventable viruses.

Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF), antiretroviral drugs used to treat HIV and hepatitis B, may be simultaneously depleting the energy of immune cells.

A retrospective study showed that exercise was found to have a protective association to adverse COVID-19 outcomes.

What is the hepatitis C treatment uptake among people who inject drugs?

Interleukin-6 receptor antagonists and antiplatelets are highly likely to improve long-term survival of critically ill adults with COVID-19, a recent study suggests.

Based on the Data and Safety Monitoring Board DSMB’s recommendation, the study will be discontinued.

Sepsis is the number 1 cause of death in hospitals. The FDA approval of IntelliSep, the first sepsis diagnostic tool, could change this.

With limited health care infrastructure and large swaths of remote areas, developing countries face difficulties in medical management with these viruses and parasitic diseases.

Therapies to reach a functional cure for hepatitis B virus may differ among the phases of hepatitis B, including new antiviral agents and immunomodulatory strategies, the study authors predicted.